Want to see AU:BIO full AI Analyst Report?
BIO Stock Chart & Stats
AU$0.28
AU$0.02(5.88%)
At close: 4:00 PM EDT
AU$0.28
AU$0.02(5.88%)
Day’s Range― - ―
52-Week RangeAU$0.20 - AU$0.53
Previous CloseN/A
Volume215.99K
Average Volume (3M)269.62K
Market Cap
AU$80.94M
Enterprise ValueAU$59.84
Total Cash (Recent Filing)AU$3.55M
Total Debt (Recent Filing)AU$2.97M
Price to Earnings (P/E)23.0
Beta1.05
Next Earnings
Feb 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding227,998,030
10 Day Avg. Volume217,764
30 Day Avg. Volume269,619
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)6.31
Price to Sales (P/S)2.48
P/FCF Ratio41.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.75Price Target Upside167.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$33.00M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue ScalingSustained multi-year revenue expansion indicates strong commercial traction and growing product adoption. A larger revenue base can improve operating leverage and support broader distribution, provided growth remains efficient and repeat purchasing continues.
Profitability TurnaroundThe shift from recurring losses to meaningful net profit strengthens the business model and internal funding capacity. If maintained, profitability can reduce reliance on external capital and provide resources for product development, marketing and distribution.
Positive Free Cash FlowPositive operating and free cash flow mark an important improvement in financial self-sufficiency. Durable cash conversion would help fund growth, service debt and absorb normal working-capital needs without repeated equity issuance or additional borrowing.
Bears Say
Cash Flow InstabilityThe recent cash-flow improvement has not yet demonstrated durability because it follows several years of cash burn, including a large outflow in 2025. Continued volatility could constrain investment and increase dependence on financing if growth consumes cash again.
Rising Debt ExposureAlthough leverage appears manageable, rising debt increases fixed financial obligations and reduces flexibility if earnings weaken. The company must sustain profitability and cash generation to prevent borrowing from limiting product investment, distribution expansion or resilience.
Operating Profitability VolatilityStrong net income growth has not fully removed concerns about underlying operating performance. Uneven operating profit suggests cost control, gross margins or commercial spending may still fluctuate, creating execution risk and making future earnings less predictable.
Biome Australia Ltd News
BIO FAQ
What was Biome Australia Ltd’s price range in the past 12 months?
Biome Australia Ltd lowest share price was AU$0.20 and its highest was AU$0.53 in the past 12 months.
What is Biome Australia Ltd’s market cap?
Biome Australia Ltd’s market cap is AU$80.94M.
When is Biome Australia Ltd’s upcoming earnings report date?
Biome Australia Ltd’s upcoming earnings report date is Feb 23, 2027 which is in 160 days.
How were Biome Australia Ltd’s earnings last quarter?
Biome Australia Ltd released its earnings results on Aug 25, 2026. The company reported AU$0.011 earnings per share for the quarter.
Is Biome Australia Ltd overvalued?
According to Wall Street analysts Biome Australia Ltd’s price is currently Undervalued.
Does Biome Australia Ltd pay dividends?
Biome Australia Ltd does not currently pay dividends.
What is Biome Australia Ltd’s EPS estimate?
Biome Australia Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biome Australia Ltd have?
Biome Australia Ltd has 227,998,030 shares outstanding.
What happened to Biome Australia Ltd’s price movement after its last earnings report?
Biome Australia Ltd reported an EPS of AU$0.011 in its last earnings report. Following the earnings report the stock price went up 7.692%.
Which hedge fund is a major shareholder of Biome Australia Ltd?
Currently, no hedge funds are holding shares in AU:BIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biome Australia Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.75 (167.86% Upside)
AU$0.75 (167.86% Upside)
Blogger Sentiment
Bullish
AU:BIO Sentiment 100%
Sector Average 62%
Sector Average 62%
Insider Transactions
Bought Shares
Worth AU$25.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Biome Australia Ltd
Biome Australia Limited, founded in 2018 and headquartered in Cremorne, Australia, specializes in the development, commercialization, and global distribution of live biotherapeutic and complementary health products. The company's product line features live biotherapeutics under the Activated Probiotics brand, organic nutritional supplements branded as Activated Nutrients, and athletic performance and recovery items named Activated X Performance. These offerings are accessible to consumers through both community pharmacies and independent health practitioners.
BIO Stock 12 Month Forecast
Average Price Target
AU$0.75
▲(167.86% Upside)
Technical Analysis
Immuron Limited
―
Avecho Biotechnology Limited
―
Anatara Lifesciences Ltd
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―